1,601 results match your criteria Vogt-Koyanagi-Harada Syndrome


De novo Vogt-Koyanagi-Harada disease after vaccination for COVID-19, successfully treated with systemic steroid therapy and monitored with laser speckle flowgraphy.

Am J Ophthalmol Case Rep 2022 Sep 11;27:101616. Epub 2022 Jun 11.

Department of Ophthalmology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Purpose: Vogt-Koyanagi-Harada (VKH) disease after vaccination for coronavirus disease 2019 (COVID-19) is rare, and the prognosis for this condition and its effect on ocular blood flow remains unclear. The purpose of this paper is to present the first case of de novo VKH disease after the second vaccination for COVID-19 with an mRNA vaccine that was successfully treated with systemic steroid therapy and monitored with laser speckle flowgraphy (LSFG).

Observations: A 30s-year-old Japanese woman reported bilateral decreased visual function 2 weeks after receiving a second dose of the BNT162b2 mRNA vaccine. Read More

View Article and Full-Text PDF
September 2022

Vogt-Koyanagi-Harada syndrome and Adie's tonic pupil: Case report.

J Fr Ophtalmol 2022 Jun 8. Epub 2022 Jun 8.

Service d'ophtalmologie, CHU d'Angers, 4, rue Larrey, 49933 Angers, France.

View Article and Full-Text PDF

Use of systemic corticosteroids in patients newly registered at a claims database with a diagnosis of non-infectious uveitis: results from a real-world claims database analysis.

Jpn J Ophthalmol 2022 Jul 7;66(4):394-404. Epub 2022 Jun 7.

Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.

Purpose: To investigate the real-world dose of systemic corticosteroids in the treatment of non-infectious uveitis (NIU) in Japan.

Study Design: A retrospective, observational study.

Methods: Patients newly registered at the Japan Medical Data Center health insurance claims database with a diagnosis of NIU who received systemic corticosteroids were identified, and their systemic corticosteroid dose (prednisolone equivalent) was assessed over 12 months of treatment (data extraction period: January 2008 to May 2017). Read More

View Article and Full-Text PDF

Chromatin accessibility analysis reveals regulatory dynamics and therapeutic relevance of Vogt-Koyanagi-Harada disease.

Commun Biol 2022 05 26;5(1):506. Epub 2022 May 26.

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, 510060, China.

The barrier to curing Vogt-Koyanagi-Harada disease (VKH) is thought to reside in a lack of understanding in the roles and regulations of peripheral inflammatory immune cells. Here we perform a single-cell multi-omic study of 166,149 cells in peripheral blood mononuclear cells from patients with VKH, profile the chromatin accessibility and gene expression in the same blood samples, and uncover prominent cellular heterogeneity. Immune cells in VKH blood are highly activated and pro-inflammatory. Read More

View Article and Full-Text PDF

Vogt-Koyanagi-Harada disease: the step-by-step approach to a better understanding of clinicopathology, immunopathology, diagnosis, and management: a brief review.

J Ophthalmic Inflamm Infect 2022 May 12;12(1):17. Epub 2022 May 12.

Retinal and Inflammatory Eye Diseases, Centre for Ophthalmic Specialised Care (COS), Lausanne, Switzerland.

Background: Appraisals of Vogt-Koyanagi-Harada disease (VKH) have become progressively more complete, since its first description in 1906. The availability of new investigational methods has improved our knowledge of the immunopathology, clinicopathology, diagnosis, and management of VKH disease. This review aimed to describe some of the steps that led to better characterization of VKH as a clinical entity. Read More

View Article and Full-Text PDF

Optical coherence tomography angiography reveals paradoxically decreasing choroidal thickness & increasing blood flow in remitting Vogt Koyanagi Harada syndrome.

Retina 2022 May 5. Epub 2022 May 5.

Watany Eye Hospital, Cairo, Egypt.

Purpose: To assess changes in choroidal thickness & blood flow in active Vogt Koyanagi Harada (VKH) syndrome and after remission using optical coherence tomography angiography (OCTA).

Methods: This was a prospective study of patients with active early uveitis secondary to VKH. They underwent OCTA imaging twice: at baseline and after remission on treatment. Read More

View Article and Full-Text PDF

Immune Activities in Choroids of Visually Impaired Smyth Chickens With Autoimmune Vitiligo.

Front Med (Lausanne) 2022 25;9:846100. Epub 2022 Apr 25.

Department of Poultry Science, University of Arkansas System Division of Agriculture, Fayetteville, AR, United States.

Vitiligo is a common dermatological disorder affecting 1-2% of the world's population. It is characterized by postnatal, autoimmune destructions of melanocytes in the skin, resulting in patches of depigmentation. Autoimmunity in vitiligo may also affect melanocytes in non-integumental tissues, including the eyes where choroidal melanocytes are the target of the autoimmune response. Read More

View Article and Full-Text PDF

Phacoemulsification after trabeculectomy in uveitis associated with Vogt-Koyanagi-Harada disease: intermediate-term visual outcome, IOP control and trabeculectomy survival.

BMC Ophthalmol 2022 May 9;22(1):210. Epub 2022 May 9.

Uveitis Division, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.

Purpose: To evaluate the visual outcome, intraocular pressure control and trabeculectomy survival after phacoemulsification in eyes with prior trabeculectomy in uveitis associated with Vogt-Koyanagi-Harada disease (VKH).

Design: Retrospective comparative study.

Methods: Eyes with uveitic glaucoma associated with VKH who underwent mitomycin C (MMC)-enhanced trabeculectomy were included. Read More

View Article and Full-Text PDF

Reflections on a case of Vogt-Koyanagi-Harada syndrome first diagnosed in internal medicine: a case report.

Ann Palliat Med 2022 Apr;11(4):1589-1594

Department of Ophthalmology, Shengli Oilfield Central Hospital, Dongying, China.

Background: A case of Vogt-Koyanagi-Harada syndrome (VKH) first diagnosed with encephalitis was reported and it bring us the clinical reflection.

Case Description: A 73-year-old Chinese woman was first diagnosed in the department of neurology with headache, nausea, vomiting, and elevated body temperature. Cerebrospinal fluid (CSF) assays showed significant increases in leukocytes and Cerebrospinal fluid total protein (CS-TP). Read More

View Article and Full-Text PDF

Novel corneal morphological alterations in Vogt-Koyanagi-Harada disease.

Jpn J Ophthalmol 2022 Jul 5;66(4):358-364. Epub 2022 May 5.

Department of Ophthalmology, Graduate School of Medicine, Osaka University, Osaka, Japan.

Purpose: To determine whether visual function, especially when dependent on the anterior segment of ocular tissue, is altered during high-dose steroid treatment for Vogt-Koyanagi-Harada disease (VKH).

Study Design: Retrospective case series METHODS: This case series included 18 eyes of 18 patients with VKH who received high-dose steroid therapy as initial treatment. All patients underwent anterior swept-source optical coherent tomography (CASIA-2) examinations during their clinical course to measure the central corneal thickness (CCT), average central corneal power (ACCP), maximum curvature (Kmax) and anterior chamber depth (ACD). Read More

View Article and Full-Text PDF

Atypical Chronic Central Serous Chorioretinopathy Mimicking Vogt-Koyanagi-Harada Disease: Full Therapeutic Response to Half-Fluence Photodynamic Therapy

Turk J Ophthalmol 2022 04;52(2):147-152

Ankara University Faculty of Medicine, Department of Ophthalmology, Ankara, Turkey

The aim of this case report is to describe a case of atypical central serous chorioretinopathy (CSCR) definitively diagnosed after 8 years. A 44-year-old woman presented with reduced visual acuity in her left eye. Her visual acuity was light perception with projection in the right eye and 0. Read More

View Article and Full-Text PDF

Mechanisms, Pathophysiology and Current Immunomodulatory/Immunosuppressive Therapy of Non-Infectious and/or Immune-Mediated Choroiditis.

Pharmaceuticals (Basel) 2022 Mar 24;15(4). Epub 2022 Mar 24.

Retinal and Inflammatory Eye Diseases, Centre for Ophthalmic Specialized Care (COS), Rue Charles-Monnard 6, CH-1003 Lausanne, Switzerland.

Non-infectious choroiditis comprises immune-mediated diseases resulting from diverse pathophysiological mechanisms. These conditions are sub-divided into two main groups, (1) diseases of the choriocapillaris and (2) diseases of the choroidal stroma. The purpose of this study is to expose the pathophysiology of the most common diseases of both these groups and recommend the optimal immunomodulatory/immunosuppressive therapy of each analyzed condition based on literature data and data from our own centers. Read More

View Article and Full-Text PDF

Progress in the genetics of uveitis.

Genes Immun 2022 Apr 4;23(2):57-65. Epub 2022 Apr 4.

Department of Medical and Molecular Genetics, Faculty of Life Sciences and Medicine, King's College London, London, England.

Uveitis is the most common form of intraocular inflammatory disease and is a significant cause of visual impairment worldwide. Aetiologically, uveitis can also be classified into infectious uveitis and non-infectious uveitis. The common non-infectious forms of uveitis include acute anterior uveitis (AAU), Behçet's disease (BD), Vogt-Koyanagi-Harada (VKH) disease, birdshot chorioretinopathy (BSCR), sarcoid uveitis. Read More

View Article and Full-Text PDF

Ocular Abnormalities in Patients with Vitiligo: A Systematic Review and Meta-Analysis.

Dermatology 2022 Apr 4:1-10. Epub 2022 Apr 4.

Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan.

Background: Vitiligo is a skin depigmentation disorder that results from the autoimmune destruction of cutaneous melanocytes. Several ocular abnormalities, including uveitis, dry eye, glaucoma, and retinal diseases, have been reported in patients with vitiligo. The aim of our study was to investigate the association of ocular abnormalities with vitiligo. Read More

View Article and Full-Text PDF

Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine.

Cells 2022 03 16;11(6). Epub 2022 Mar 16.

Service of Ophthalmology, Instituto de Investigación Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain.

We describe a case of Vogt-Koyanagi-Harada (VKH) disease exacerbation after COVID-19 vaccination. A 46-year-old woman presented with a bilateral granulomatous uveitis 2 days after the first dose of COVID-19 mRNA vaccine (Comirnaty, Pfizer-BioNTech), and was diagnosed with a complete Vogt-Koyanagi-Harada (VKH) disease 4 days after receiving the second dose of the vaccine. Three weeks before the first dose, she had been consulted for blurred vision and mild headaches. Read More

View Article and Full-Text PDF

Vogt-Koyanagi-Harada disease - A diagnostic pitfall for neurologists.

eNeurologicalSci 2022 Mar 23;26:100390. Epub 2021 Dec 23.

Department of Neurology, Seoul National University College of Medicine, Seoul, Republic of Korea.

•VKH is an idiopathic autoimmune disease presenting with uveomeningeal syndrome.•Granulomatous uveitis and serious retinal detachments are the most common findings of VKH.•VKH can masquerade as IIH by presenting with severe headache and optic disc edema. Read More

View Article and Full-Text PDF

Brentuximab vedotin induced uveitis.

Am J Ophthalmol Case Rep 2022 Jun 18;26:101440. Epub 2022 Feb 18.

ZNA Middelheim, Lindendreef 1, 2020, Antwerp, Belgium.

Purpose: To report a case of bilateral Vogt-Koyanagi-Harada (VKH)-like granulomatous pan uveitis secondary to brentuximab vedotin (BV) administration to treat for classical Hodgkin lymphoma (CHL).

Observations: A case of bilateral pan uveitis is described, following administration of BV, with features of VKH-like uveitis: presence of inflammatory cells in the anterior and posterior segment, multiple small serous detachments around the optic disc and retinal pigment epithelium (RPE) folds confirmed by optical coherence tomography (OCT) as well as hypocyanesent dark dots, disc hyperfluorescence and fuzzy vascular patterns seen on indocyanine green and fluorescein angiography. There were no systemic features of VKH disease. Read More

View Article and Full-Text PDF

Objective evaluation of choroidal melanin loss in patients with Vogt-Koyanagi-Harada disease using polarization-sensitive optical coherence tomography.

Sci Rep 2022 03 3;12(1):3526. Epub 2022 Mar 3.

Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.

In this study, sunset glow fundus was evaluated in patients with Vogt-Koyanagi-Harada (VKH) disease using polarization-sensitive optical coherence tomography (PS-OCT). We evaluated 40 VKH eyes (20 patients) and 59 healthy eyes (59 age-matched controls). VKH eyes were divided into three groups according to color fundus images: sunset (17 eyes), potential sunset (13 eyes), and non-sunset (10 eyes). Read More

View Article and Full-Text PDF

Annular Streaklike Subretinal Fibrosis in Vogt-Koyanagi-Harada Syndrome.

JAMA Ophthalmol 2022 02 17;140(2):e215107. Epub 2022 Feb 17.

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, People's Republic of China.

View Article and Full-Text PDF
February 2022

Enriched and Decreased Intestinal Microbes in Active VKH Patients.

Invest Ophthalmol Vis Sci 2022 02;63(2):21

Ophthalmologic Center of the Second Hospital, Jilin University, Changchun, P.R. China.

Purpose: To determine the possible microbiome related to Vogt-Koyanagi-Harada (VKH) disease in comparison to patients with noninfectious anterior scleritis and healthy people.

Methods: Fecal samples were extracted from 42 individuals, including 11 patients with active VKH, 11 healthy people, and 20 patients with noninfectious anterior scleritis. We amplified the V3 to V4 16S ribosomal DNA (rDNA) region to obtain the target sequence. Read More

View Article and Full-Text PDF
February 2022

Unusual neurologic manifestations of Vogt-Koyanagi-Harada disease: a systematic literature review.

BMC Neurol 2022 Feb 4;22(1):44. Epub 2022 Feb 4.

Department of Medicine and Medical Specialties, Regional Hospital Center of Dosso, Dosso, Niger.

Background And Purpose: The usual neurologic manifestations of Vogt-Koyanagi-Harada (VKH) disease include aseptic meningitis and headaches. We performed the present study to review all unusual neurologic manifestations reported in VKH disease to summarize them.

Methods: A literature search was performed in the English language on Scopus and Medline via PubMed from 1946 to July 31, 2021, by using the following terms: "Vogt Koyanagi Harada disease" OR "VKH disease" AND "Brain" OR "Spinal cord" OR "CNS" OR "Central nervous system" OR "Neurologic" OR "Peripheral nervous system" OR "Polyneuropathies. Read More

View Article and Full-Text PDF
February 2022

Multimodal Imaging Approach in a Patient with Vogt-Koyanagi-Harada-like Syndrome Due to Dabrafenib and Trametinib Use for Cutaneous Melanoma.

Ocul Immunol Inflamm 2022 Feb 3:1-5. Epub 2022 Feb 3.

U.O. Oculistica 2, Turin Eye Hospital, ASL Città di Torino, Turin, Italy.

Purpose: To describe a case of ocular inflammation associated with dabrafenib and trametinib chemotherapy for cutaneous melanoma by using a multimodal image approach.

Materials And Methods: We report on a 51-year-old woman with Vogt-Koyanagi-Harada-like syndrome, which occurred while she was undergoing treatment with dabrafenib and trametinib for cutaneous melanoma. The patient complained of sudden, bilateral vision loss of 2 days' duration. Read More

View Article and Full-Text PDF
February 2022

MICROBIOME AND UVEITIDES. A REVIEW.

Cesk Slov Oftalmol 2022 ;78(2):47-52

Microorganisms inhabiting all surfaces of mucous membranes and skin and forming a complex ecosystem with the host is called microbiota. The term microbiome is used for the aggregate genome of microbiota. The microbiota plays important role in the mechanisms of number of physiological and pathological processes, especially of the hosts immune system. Read More

View Article and Full-Text PDF
February 2022

Case Report: Vogt-Koyanagi-Harada Syndrome Mimicking Acute Angle-Closure Glaucoma in a Patient Infected With Human Immunodeficiency Virus.

Authors:
Xue Bai Rui Hua

Front Med (Lausanne) 2021 12;8:752002. Epub 2022 Jan 12.

Department of Ophthalmology, First Hospital of China Medical University, Shenyang, China.

Vogt-Koyanagi-Harada disease (VKH) is a rare multisystemic inflammatory autoimmune disorder. Glaucoma secondary to VKH frequently occurs during the recurrent phase of anterior uveitis; however, acute angle-closure glaucoma (ACG) secondary to both VKH and human immunodeficiency virus (HIV) infection has rarely been reported. We describe a case of secondary acute ACG involving VKH, characterized by sudden vision loss, moderately elevated intraocular pressure (IOP), shallow anterior chamber, and fully or partially closed angle, in an HIV-infected patient. Read More

View Article and Full-Text PDF
January 2022

The emerging role of epigenetics and gut microbiota in Vogt-Koyanagi-Harada syndrome.

Gene 2022 Apr 29;818:146222. Epub 2022 Jan 29.

School of Basic Medical Sciences, Special Key Laboratory of Ocular Diseases of Guizhou Province, Zunyi Medical University, Guizhou 563000, China. Electronic address:

Vogt-Koyanagi-Harada (VKH) syndrome is an autoimmune disorder characterized often by acute diffuse uveitis, also known as idiopathic uveoencephalitis. The associated complications can potentially affect multiple systems throughout the body, including eyes, ears, skin and nervous system. Although the pathogenesis of VKH syndrome remains unclear, it has been established that the various genetic factors, epigenetic factors and the imbalance in immune regulation can significantly contribute to the development of this disease. Read More

View Article and Full-Text PDF

Vogt Koyanagi Harada disease following a recent COVID-19 infection.

Indian J Ophthalmol 2022 Feb;70(2):670-672

Retina - Vitreous Services, Aravind Eye Hospital, Chennai, Tamil Nadu, India.

A 23-year-old female presented with a 3-day history of bilateral (OU) diminution of vision 3 weeks after COVID-19 infection. Best corrected visual acuity (BCVA) was 20/30 in right eye and 20/40 in left eye. Anterior segment showed OU 1+ cells in anterior chamber and anterior vitreous face. Read More

View Article and Full-Text PDF
February 2022

Progranulin Suppressed Autoimmune Uveitis and Autoimmune Neuroinflammation by Inhibiting Th1/Th17 Cells and Promoting Treg Cells and M2 Macrophages.

Neurol Neuroimmunol Neuroinflamm 2022 03 26;9(2). Epub 2022 Jan 26.

From the First Affiliated Hospital of Chongqing Medical University, Chongqing Key Lab of Ophthalmology, Chongqing Eye Institute, Chongqing Branch of National Clinical Research Center for Ocular Diseases, China.

Background And Objectives: Progranulin (PGRN) is an important immune regulatory molecule in several immune-mediated diseases. The objective of this study is to investigate the role of PGRN in uveitis and its counterpart, experimental autoimmune uveitis (EAU), and experimental autoimmune encephalomyelitis (EAE).

Methods: Serum PGRN levels in patients with Behcet disease (BD) or Vogt-Koyanagi-Harada (VKH) disease and normal controls were measured by ELISA. Read More

View Article and Full-Text PDF

Characteristics, Upon Presentation, of a Cohort of Patients with Vogt-Koyanagi-Harada Disease in Puerto Rico.

P R Health Sci J 2021 11 18;40(4):168-173. Epub 2021 Nov 18.

Department of Ophthalmology, University of Puerto Rico, San Juan, PR.

Objective: To describe the clinical features, upon initial presentation, of a cohort of patients with Vogt-Koyanagi-Harada (VKH) disease who live in Puerto Rico.

Methods: A retrospective medical record review of patients with VKH was performed. The demographic and clinical characteristics were analyzed. Read More

View Article and Full-Text PDF
November 2021